Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd Combinations in Solid Tumors (TROPION-PanTumor04)
NCT07890714Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan in urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2026; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07890714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890714.